Skip to content
Subscriber Only

Astra Confident Shareholders Will Back $39 Billion Alexion Deal

  • Astra, Alexion investors due to vote on purchase on Tuesday
  • Takeover is not a defensive move, CFO says in interview
AstraZeneca Plc Raises Sales Forecast as New Cancer Treatments Gain
Photographer: Mikael Sjoberg/Bloomberg

AstraZeneca Plc is confident shareholders will back its $39 billion takeover of rare-disease specialist Alexion Pharmaceuticals Inc. next week as the British company looks to the next chapter of its growth.

“It is quite rare to find somebody who says it’s not a good idea, so we are confident that this will turn out OK,” Marc Dunoyer, the drugmaker’s chief financial officer, said in an interview Thursday. The deal marks “the next stage” in Astra’s growth trajectory, he said.